PolyNovo
Australia - Port MelbourneBiotechnology
Focus: PolyNovo is a publicly listed Australian biotech company specializing in biodegradable biomaterials for dermatological and wound care applications. The company is focused on commercializing its proprietary NovoSorb platform across burns, hidradenitis suppurativa, and diabetic foot ulcer indications.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Total Funding
$25M
Open Jobs
17
Should You Work at PolyNovo?
AI assessmentPolyNovo is best suited for mid-career professionals seeking commercialization experience in a specialized biotech niche, but limited transparency and R&D depth may constrain long-term scientific growth.
Why Work Here
- Commercialization-focused hiring (9 of 16 roles in Commercial) signals active market expansion and revenue-generation phase
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
NovoSorb BTM
Growing
Growth
Flagship product targeting acute burn wound management; appears to be the company's lead commercial asset.
NovoSorb BTM
Help build intelligence for PolyNovo
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.